Black Sheep (2006) - Trailer
Directed by Jonathan King "An experiment in genetic engineering turns harmless sheep into blood-thirsty killers that terrorize a sprawling New Zealand farm." (by imdb.com)From:PyrkensteinViews:3 0ratingsTime:01:59More inFilm Animation
More:
Mike #39;s Beautiful Life Excerpt - Genetic Engineering
This is an eight minute excerpt from Mike #39;s Beautiful Life, which explains why genetic engineering is one of the most dangerous developments humans will ever face. For more information, visit http://www.ravediet.comFrom:Mike AndersonViews:6 1ratingsTime:08:20More inNews Politics
Excerpt from:
Impacts of Genetic Engineering
From:Emily WorkmanViews:3 0ratingsTime:04:06More inEducation
More:
Port Townsend Food Coop: How To Collect Signatures For GMO Labeling Initiative 522
How to set-up the I-522 signature gathering table at the Port Townsend Food Coop. If you would like to collect i-522 signatures at the PT Food Coop, contact Kathie Meyer (kathie@foodcoop.coop, 360.385.2831 x309) to get on the calendar. Fall 2012 Newsletter Article (Page 16) GMOs: It #39;s Our Right to Know Beverly Goldie, Food Co-op Owner Concerned Activist foodcoop.coop "...More than 20states have attempted to pass GMO labeling bills through government processes including Oregon, Vermont, Connecticut, Colorado, and New York -- and in each case the attempts have been thwarted by big corporations using extensive lobbying or threats to sue the states... ...If you live in the Port Townsend area, please visit the Co-op to sign the initiative. Let your voice join the thousands of other so we can be heard." Interview with Beverly Goldie (Part 1) http://www.youtube.com Video Interview: "I want my food untainted by GMOs" youtu.be Deb Shortess Food Coop Port Townsend - Our GMO Awareness Program http://www.youtube.com I-522 is an initiative to the Washington State legislature to establish mandatory labeling of foods produced through genetic engineering. As recommended by the Secretary of State, the LabelitWA group needs to turn in at least 320000 signatures to ensure they have 241153 valid signatures by December 31, 2012 in order to get on the November 2013 ballot. I-522, "The People #39;s Right to Know Genetically Engineered Food Act," is simple. The initiative would require food sold in retail ...From:digitalreporterViews:5 0ratingsTime:01:55More inTravel Events
Read more:
Port Townsend Food Coop: How To Collect Signatures For GMO Labeling Initiative 522 - Video
Giants, Planet X, Illuminati and More with Steve Quayle
Author and researcher Steve Quayle riffed on a variety of topics such as giants, weather modification, secret aircraft, biblical prophecy, genetic engineering, the Illuminati agenda, and Planet X. The machinery to affect weather has gotten smaller and cheaper over the years, and there are currently 72 ionospheric heaters, in addition climate-controlling technology like Project HAARP, he outlined. Sightings of silent triangular-shaped craft are on the rise, and a battle in outer space is imminent, said Quayle, naming "extra-dimensionals" and black-ops as some of the participants. The "super-soldier" program, Stargate technology, and CERN are involved in efforts to re-animate ancient giants, who were some 12-18 ft. height, he declared. "We are experiencing now the full implementation, in my opinion, of the Luciferian war on humanity. We talk about the New World Order, the Illuminati, the International League, but what is the prime directive of all those entities? It #39;s the destruction of a five and half billion people," he cautioned. Quayle reported his recent conversation with a "high ranking Goldman Sachs official" who #39;d visited one of the elite #39;s underground cities that was being prepared. The official warned him that a "global flu" had already been determined, and a mandatory vaccination will be required, with those who refuse to take it being sent to FEMA camps. On the subject of Planet X, Quayle suggested that we #39;re already seeing its effects throughout the solar ...From:DiscloseTruthTVViews:1140 11ratingsTime:01:16:44More inEducation
Read this article:
Giants, Planet X, Illuminati and More with Steve Quayle - Video
Watch Real Life Superhero Muscles Like Marvel #39;s The Avengers - The Avengers: Real Life Avengers
Watch full movie here : free-hot-movies.com Avengers The Avengers The Iron Man (Fictional Character) Theme Music (Musical Genre) Kanye West (Musical Artist) heroic imagination project Neha Dhupia (Film Actor) Real Life the avengers politics obama bradley manning tribeca film festival The Avengers movie Automobile (Industry) marvels the avengers obama whistleblowers genetic engineering government secrecy obama transparency Scarlett Johansson Ashutosh Gowarikar end credits scene captain america 2 Real Life Sucks martian manhunter manning wikileaks Super Fly Comics robert downey jr real life heroes Robert Downey Jr Kinsey Schofield leaked documents Chris Hemsworth how to be happy Captain America captain america bradley manning young hollywood philip zombardo the avengers 2 avengers movie lucifer effect find happiness Superhero captainamerica acuransxspyder In film festival Sudhir Mishra Ranvir Shorey The Cinecurry Hulk (comics) Marvel watchthedaily Healthcare Assemble Superman who marvel movie episode Sushma Reddy Anees Bazmee black widow kommentatorz Captain America Carly Steel joss whedon Neha Dhupia movie news 2asiandudesFrom:MarcellusColaiacovoViews:0 0ratingsTime:08:51More inFilm Animation
Visit link:
gene-X, Genetic engineering the Movie Official Trailer.mp4
This is the official traier of the short film "gene-X", made for the genetic engineering project by M.Sc. Biotechnology final year Students from VIT University, Vellore. (2011-13 Batch) Hope you will enjoy! Movie will go on air soon! Thank youFrom:Prasanna KarandikarViews:1 1ratingsTime:02:01More inPeople Blogs
Read this article:
gene-X, Genetic engineering the Movie Official Trailer.mp4 - Video
Foods, Diet Nutrition: Nutrient Density, Pesticides Genetically Engineered Foods
Arden B. Anderson, DO, Ph.D., MSPH presents a compelling presentation at the "12th Clinical Applications for Age Management Medicine Conference" May 2012, Hollywood, FL Foods, Diet and Nutrition: What a Clinician Needs to Know About Nutrient Density, Pesticides and Genetically Engineered Foods Arden B. Anderson, DO, Ph.D., MSPH Medical Director, Crossroads Healing Arts, Goshen, IN Professional Food Production Consultant / Author / Instructor Lecture objectives: bull; Describe the link between soil health and human health bull; Explain how genetic engineering of foods creates a snowball effect of health decline, nutrient deficiency and disease expansion in human and animal consumersFrom:AgeManagmentMedicineViews:0 0ratingsTime:08:29More inEducation
Here is the original post:
What is Proposition 37 - My Green Life
My Green Life #39;s topic today is Proposition 37. And we have an expert to talk about this: Vinnie Tortorich, host of his own podcast show, "America #39;s Angriest Trainer". The initiative simply requires food sold in retail outlets to be labeled if it is produced through genetic engineering, and would not allow these products to be labeled as "natural." Prop 37 gives companies 18 months to change their labels, and allows for the GMO disclosure to appear wherever they choose on packaging. Please, Vote YES on 37 because We have the right to know what #39;s in our food! My Green Life is presented by Tiffany Paige. To find out more about TreeLiving please visit our website and follow us on Twitter and Facebook here: http://www.treeliving.com http http://www.Facebook.com twitter.com pinterest.com tree-living.tumblr.com httpFrom:TreeLivingShowsViews:1 0ratingsTime:05:04More inFilm Animation
View post:
Genetics-Iran-11-04-2012
DesiGirlsNetwork.Blogspot.com http Updates World News Plz Subscrib for Latest World News Iranian scientists have been working in the field of genetics for half of a century. Today the institute of genetic engineering and biotechnology is one of the leading research centers in the region. Its activities are aimed at enhancing the quality of life by better food medicine and environment. Amir Mehdi Kazemi reports on genetic engineering and biotechnology in Iran. Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.comFrom:UpdatesWorldNewsViews:0 0ratingsTime:06:41More inNews Politics
Original post:
Public release date: 5-Nov-2012 [ | E-mail | Share ]
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, November 5, 2012Spinal cord injury (SCI) can disrupt the body's sensitive signaling mechanisms that control blood pressure, breathing, and oxygen delivery to the heart and other organs during changes in body position. Cardiovascular (CV) disease is a leading cause of illness and death following SCI, and changes in baroreflex sensitivitythe body's ability to detect and respond to changes in blood pressuremay be predictive of a CV event. A comprehensive review article on baroreflex sensitivity after SCI is published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website at http://www.liebertpub.com/neu.
Aaron Phillips, Andrei Krassioukov, Philip Ainslie, and Darren Warburton, University of British Columbia, Vancouver, B.C., Canada, detail the current techniques available to measure baroreflex function, describe the mechanisms and role of normal baroreflex function, and summarize the body of literature on baroreflex function after SCI. In the article "Baroreflex Function after Spinal Cord Injury," the authors propose potential mechanisms to explain the baroreflex dysfunction that can occur following SCI and they recommend directions for future research studies.
"In addition to altering motor function, spinal cord injury can produce a range of serious complications including cardiovascular dysfunction and other quality of life issues," says Journal of Neurotrauma Deputy Editor W. Dalton Dietrich III, PhD, Scientific Director, The Miami Project to Cure Paralysis, and Kinetic Concepts Distinguished Chair in Neurosurgery, Professor of Neurological Surgery, Neurology and Cell Biology at University of Miami Leonard M. Miller School of Medicine, Lois Pope LIFE Center. "This informative review article by an expert panel of researchers provides new information regarding mechanisms underlying autonomic dysfunction in people living with SCI. More attention and research are needed to develop and test new treatments targeting the causes of baroreflex dysfunction after SCI that can improve cardiovascular function in these individuals."
###
About the Journal
Journal of Neurotrauma is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. Journal of Neurotrauma is the Official Journal of the National Neurotrauma Society and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the Journal of Neurotrauma website at http://www.liebertpub.com/neu.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Therapeutic Hypothermia and Temperature Management, Tissue Engineering, and Brain Connectivity. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.
Read the rest here:
Spinal cord injury puts patients at high risk of life-threatening cardiovascular events
Glycoanalysis company ProCognia (Israel) Ltd. (TASE:PRCG) is expanding its collaboration with Norway's UniTargetingResearch AS (UTR) for the production of biosimilars (generic biological drugs). ProCognia is expanding its license for the exclusive use and commercialization of UTR's proprietary and patent-protected technology for improving the production of proteins by the biosimilars industry. The technology makes it possible to boost production of biological molecules created by genetic engineering.
ProCognia's share price rose 5.5% by early afternoon to NIS 0.67, giving a market cap of NIS 12 million.
Under the new agreement, ProCognia will undertake collaborations on the basis of UTR's platform, and will develop a biosimilar of a brand biological drug which currently has billions of dollars in annual sales. ProCognia believes that the biosimilar has reached the stage of possible commercialization.
ProCognia says that the biosimilars market is expected to reach billions of dollars in the coming years. Biological drugs are mostly sugar-bearing proteins for the treatment of cancers and autoimmune diseases. The expanded agreement with UTR is a milestone for the development of the platform for increasing production of bio-better proteins and in the cell's excretion of the proteins for the production of biological drugs.
ProCognia adds that the license for the development of cells which express biosimilar and biobetter products, together with the company's proprietary glycoanalysis (analysis of sugar structures in proteins) technology, puts it in a competitive position for the development of biosimilar drugs. The renewed agreement also gives the company potential revenue from its current collaboration with UTR.
ProCognia's GlycoScope is an integrated technological platform for the analysis of recombinant monoclonal antibodies and complex biopharmaceutical glycoproteins. UTR, a spin-off from the University of Bergen, has developed genetic engineering technology for enhancing the production of proteins by adding genetically engineered DNA sequences which increase production.
Published by Globes [online], Israel business news - http://www.globes-online.com - on November 6, 2012
Copyright of Globes Publisher Itonut (1983) Ltd. 2012
See the rest here:
Disorders Of Hemoglobin - , Bernard G. Forget
ll4.me Disorders Of Hemoglobin - , Bernard G. Forget This book is a completely revised new edition of the definitive reference on disorders of hemoglobin. Authored by world-renowned experts, the book focuses on basic science aspects and clinical features of hemoglobinopathies, covering diagnosis, treatment, and future applications of current research. While the second edition continues to address the important molecular, cellular, and genetic components, coverage of clinical issues has been significantly expanded, and there is more practical emphasis on diagnosis and management throughout. The book opens with a review of the scientific underpinnings. Pathophysiology of common hemoglobin disorders is discussed next in an entirely new section devoted to vascular biology, the erythrocyte membrane, nitric oxide biology, and hemolysis. Four sections deal with #65533;? #65533; #65533;? #65533; and #65533;? #65533; thalassemia, sickle cell disease, and related conditions, followed by special topics. The second edition concludes with current and developing approaches to treatment, incorporating new agents for iron chelation, methods to induce fetal hemoglobin production, novel treatment approaches, stem cell transplantation, and progress in gene therapy.Author: Steinberg, Martin H. Author: Forget, Bernard G. Author: Higgs, Douglas R. Publisher: Cambridge University Press Illustration: N Language: ENG Title: Disorders of Hemoglobin Pages: 00848 (Encrypted PDF) On Sale: 2009-06-30 SKU-13/ISBN: 9780521875196 ...From:marylloyd321Views:0 0ratingsTime:00:13More inPeople Blogs
Link:
27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology
In theory, gene therapy offers a straight forward to the molecular treatment of various diseases, by using genes to prevent or treat disease by: Replacing a mutated gene(s) with a healthy copy; Inactivating/knocking out a mutated gene; or, Introducing new gene. Gene Therapy offers an approach to treating disease by either modifying the expressions of an individual #39;s genes or correction of abnormal genes. While this seems straight forward (ie replace or supply a healthy insulin gene in pancreatic cells of a diabetic) it has been difficult to actualize. Think here also about dual use problems (ie genetic doping for athletes, genetic modification enhancement for military personnel, and germline genetic engineering of humans with heritable genes). in this section we also review tissue engineering and some of the possibilities for nanotechnologies in medical devices. Nanosized GPS capable computers in our bloodstream?From:Albert KauschViews:1 0ratingsTime:36:53More inScience Technology
Original post:
27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology - Video
James Bond - Die Another Day Watch Online Free, part 1 of 7, full lenght movie
James Bond - Die Another Day In the pre-title sequence, James Bond and his two South Korean allies infiltrate a North Korean military base belonging to Colonel Tan-Sun Moon, an army officer who is illegally selling weaponry in exchange for African conflict diamonds. Bond poses as a weapons dealer, rigging his briefcase of diamonds with C4. He meets Moon and his assistant, Zao. After the diamonds are handed over, Zao discovers Bond #39;s true identity and informs Moon. Fearing retribution from his father, General Moon, the Colonel then flees in a large hovercraft. Bond detonates the C4, embedding several diamonds in Zao #39;s face. He then steals another hovercraft and chases Moon, who tumbles into a waterfall. Soon after, North Korean troops capture Bond under General Moon #39;s orders and he is imprisoned and tortured. Fourteen months later, Bond is released in exchange for Zao, who was captured during that time. He is sedated and taken to meet M, who informs him that his status as a 00 Agent is suspended due to her belief that he may have leaked information under duress. Still bitter over Zao #39;s release, Bond decides to complete his mission by evading MI6 #39;s security and travels to Cuba. He traces Zao to an island called Isla Los Organos, known for its gene therapy "Clinic" which allows patients to have their appearances changed. On the coast, he meets a NSA agent Giacinta #39;Jinx #39; Johnson. With her help, Bond locates Zao #39;s room inside the clinic and briefly tortures him. Zao flees in aFrom:glasefclerko1986Views:0 0ratingsTime:04:06More inEntertainment
Follow this link:
James Bond - Die Another Day Watch Online Free, part 1 of 7, full lenght movie - Video
Lysosomal Storage Disorders
ll4.me Lysosomal Storage Disorders From Lysosomes to Storage Diseases and Back: A Personal Reminiscence.- Lysosomal Biogenesis and Disease.- The Concept of Treatment in Lysosomal Storage Diseases.- Complex Lipid Catabolism.- Retroviral Vectors for Gene Therapy.- Adenovirus in Gene Therapy.- Setting Back the Clock: Adenoviral-Mediated Gene Therapy for Lysosomal Storage Disorders.- Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders.- Herpes Simplex Virus Vectors for Gene Therapy of Lysomal Storage Disorders.- Gene Therapy of Lysosomal Storage Disorders by Lentiviral Vectors.- Substrate Reduction Therapy.- Newborn Screening for Lysosomal Storage Disorders.- Genetic Counseling for Lysosomal Storage Diseases.- Neural Stem Cell Therapy in Lysosomal Storage Disorders.- The GM1 Gangliosidoses.- The GM2 Gangliosidoses.- Acid Sphingomyelinase-Deficient Niemann-Pick Disease.- Krabbe Disease (Globoid Cell Leukodystrophy).- Metachromatic Leukodystrophy.- Fabry Disease.- Gaucher Disease: Review and Perspectives on Treatment.- Therapeutic Goals in the Treatment of Gaucher Disease.- The Neuronal Ceroid Lipofuscinoses: Clinical Features and Molecular Basis of Disease.- Mucopolysaccharidosis I.- Mucopolysaccharidosis II.- Sanfilippo Syndrome: Clinical Genetic Diagnosis and Therapies.- Mucopolysaccharidosis IV (Morquio Syndrome; MPS IV).- Mucopolysaccharidosis Type VI (MPS VI, Maroteaux-Lamy Syndrome).- Mucopolysaccharidosis Type VII (Sly Disease): Clinical, Genetic ...From:davidbrown9865Views:0 0ratingsTime:00:13More inPeople Blogs
Read this article:
CF Gene Therapy
News clip on new gene therapy shot coming next year to treat CF possibly...From:AH FrenchViews:0 0ratingsTime:02:25More inEducation
Link:
genetherapy eyes
A BBC item about a new gene therapy for a specific eye sight problemFrom:kees fieggenViews:0 0ratingsTime:02:42More inEducation
See the article here:
A gene-therapy medicine has been given commercial approval in Europe for the first time.
The treatment, Glybera, is designed to help those suffering from lipoprotein lipase deficiency -- an inherited disorder which sees patients unable to break down fats and can lead to life-threatening pancreatitis attacks.
Glybera -- the brand name for alipogene tiparvovec -- works on the genetic level by using a virus to implant working copies of the lipoprotein lipase gene into muscle cells, thus enabling production of the enzyme in those cells.
The first country to approve a gene therapy for commercial use was China in 2003 but gene therapy in Europe has, until now, been restricted to research laboratories.
Jorn Aldag, CEO of Glybera creators UniQure, said: "The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need."
The treatment is expected to come to market in 2013.
Image: Shutterstock
See the original post:
Treatment proves safe and effective, helps cancer survivors with chronic dry mouth
These initial results clear the way for additional gene therapy studies in the salivary glands. Although sometimes overlooked, salivary glands present an ideal target for gene therapy. They are easily accessible and, once a gene is introduced, it has no obvious escape route into the bloodstream, where it can have unintended consequences.
"You cannot imagine how fulfilling it is to jot down an idea on a napkin in 1991 and then see it enter a clinical trial and help people.," said Bruce Baum, D.M.D., Ph.D., lead author on the study and recently retired NIDCR scientist who spent the last 21 years moving gene therapy in the salivary glands from the research bench to the clinic. "Can a scientist ask for anything better?"
Baum's interest in helping head and neck cancer survivors dates to the early 1980s. While attending to patients in the NIDCR's Dry Mouth Clinic, Baum encountered numerous people with head and neck cancer who had received radiation therapy to shrink their tumors. The radiation, while effective in treating cancer, had inadvertently damaged nearby salivary glands, compromising their ability to secrete saliva into the mouth.
Baum said he was thoroughly frustrated at the time because he had no effective moisture-restoring treatments to offer most patients. They had beaten cancer, but the radiation had left them with a permanent parched sensation in their mouths that diminished their quality of life and often led to chronic oral problems, such as difficulty swallowing, inflammation, infection, bad breath, and pain.
In the early 1990s, as the first gene-therapy studies entered research clinics, Baum saw an opportunity to make a difference. An initial napkin sketch of the procedure and 15 years of research later, Baum and his colleagues had assembled a compelling scientific case in animal studies that the transferred Aquaporin-1 gene, once expressed, will create new water channels in the impermeable salivary gland cells and allow water to flow through them. After rigorous reviews by NIH and the U. S. Food and Drug Administration, the Phase I protocol was launched and the first patients treated in 2008.
The scientists gave 11 head and neck cancer survivors a single-dose injection of the Aquaporin-1 gene directly into one of their two parotid salivary glands, the largest of the major salivary glands. The gene was packaged in a disabled, non-replicating adenovirus, the cause of the common cold when intact but incapable of causing a cold in this case. As is standard in gene therapy studies, the virus served as the vector, or Trojan horse, to deliver the gene into the cells lining the salivary gland.
The scientists found that five participants had increased levels of saliva secretion, as well as a renewed sense of moisture and lubrication in their mouths, within the study's first 42 days, the period covered in this report. Of the six who didn't benefit from gene therapy, none had serious side effects. The most common side effect was a transient and relatively minor immune response against the disabled adenovirus.
"It is time to evaluate a different vector to deliver the Aquaporin-1 gene, one that will cause only a minimal immune response," said Baum. "But these data will serve as stepping stones for other scientists to improve on this first attempt in the years ahead. The future for applications of gene therapy in the salivary gland is bright."
Read the rest here:
Gene Therapy Can be Performed Safely in the Human Salivary Gland